IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0687851
(2010-01-14)
|
등록번호 |
US-8216566
(2012-07-10)
|
발명자
/ 주소 |
- Paludan, Casper
- Edinger, James W.
- Harbacheuski, Ryhor
- Murray, RoseAnn
- Hariri, Robert J.
|
출원인 / 주소 |
- Anthrogenesis Corporation
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
6 인용 특허 :
218 |
초록
▼
The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and
The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
대표청구항
▼
1. A method of treating an individual having multiple sclerosis comprising administering a therapeutically effective amount of placental stem cells to the individual in an amount sufficient to detectably improve one or more symptoms of multiple sclerosis in the individual, wherein said placental ste
1. A method of treating an individual having multiple sclerosis comprising administering a therapeutically effective amount of placental stem cells to the individual in an amount sufficient to detectably improve one or more symptoms of multiple sclerosis in the individual, wherein said placental stem cells detectably suppress T cell proliferation stimulated by Epstein-Barr virus antigen-presenting B cells; and wherein at least 80% of said placental stem cells express CD200. 2. The method of claim 1, comprising administering 1 million to 10 billion placental stem cells to said individual. 3. The method of claim 2, comprising administering 1×106 placental stem cells to said individual. 4. The method of claim 2, comprising administering 1×107 placental stem cells. 5. The method of claim 2, comprising administering 1×108 placental stem cells. 6. The method of claim 2, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are OCT-4+. 7. The method of claim 2, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are one or more of CD34−, CD38−, or CD45−. 8. The method of claim 6, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are one or more of CD34−, CD38−, or CD45−. 9. The method of claim 2, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are CD10+ or CD105+. 10. The method of claim 6, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are CD10+ or CD105+. 11. The method of claim 2, wherein said at least 80% of said 1 million to 10 billion said placental stem cells are CD10+, CD34−, CD105+ and CD200+. 12. The method of claim 1, wherein said one or more symptoms comprises or more of a sensory disturbance in the limbs, an optic nerve dysfunction, a pyramidal tract dysfunction, a bladder dysfunction, a bowel dysfunction, a sexual dysfunction, ataxia, or diplopia. 13. The method of claim 1, wherein said individual demonstrates and improvement on the Expanded Disability Status Scale of at least one point. 14. The method of claim 1, wherein said individual demonstrates and improvement on the Expanded Disability Status Scale of at least two points. 15. The method of claim 1, wherein said individual has relapsing/remitting multiple sclerosis or progressive/relapsing multiple sclerosis. 16. The method of claim 1, wherein said individual has secondary progressive multiple sclerosis or primary progressive multiple sclerosis. 17. The method of claim 1, wherein said placental stem cells are administered during an acute attack of multiple sclerosis in said individual. 18. The method of claim 1, comprising administering a second type of stem cell to said individual. 19. The method of claim 18, wherein said second type of stem cell is mesenchymal stem cells from bone marrow. 20. The method of claim 1, additionally comprising administering to said individual a therapeutic agent, wherein said therapeutic agent is adrenocorticotropic hormone (ACTH), methylprednisolone, dexamethasone, IFNβ-1a, IFN-1b, gliatriamer acetate, cyclophosphamide, methotrexate, azathioprine, cladribine, cyclosporine, mitoxantrone, or sulfasalazine. 21. The method of claim 1, wherein said placental stem cells have been cryopreserved prior to said administration. 22. The method of claim 1, wherein said placental stem cells have been passaged no more than 10 times prior to said administration.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.